© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#AASLD 2012
Click Here for More Conferences
Click Here for AASLD.org
An Introduction to Hepatitis

Baby Boomers With Hepatitis C Drive Demand for Liver Transplants

Aging baby boomers make up the greatest demand for hepatitis C-related liver transplantations in the United States.

Abbott Announces Phase III Trials of Its Potent Hep C Direct Acting Agents

Abbott has announced Phase III trials of three direct acting agents, ABT-450/r, ABT-267, ABT-333, which together have shown high cure rates in...

Long-term Entecavir Is Safe and Effective for Hep B Patients, Even with Cirrhosis

Entecavir has shown safety and efficacy over a five-year period in people with hepatitis B who haven’t yet tried treatment with nucleos(t)ide...

Daclatasvir, Asunaprevir Regimens Boast High Cure Rates in Hard-to-Treat Hep C

Investigational agents daclatasvir and asunaprevir have shown high cure rates among prior null-responders with difficult-to-treat strains of h...

Interferon-Free Hep C Treatment With Faldaprevir is Safe & Effective

Antiviral therapies faldaprevir and BI 207127 are safe and effective among people with hepatitis C virus, including those with advanced liver...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Tenofovir Is Safe and Effective for Hep B, Yields Little Bone Loss

Tenofovir is safe and effective for long-term treatment of hepatitis B, and leads to few kidney-related side effects and no clinically relevan...

Liver Cancer Spikes Among Spanish Coinfected With HIV, Hepatitis

Spanish researchers have sounded the alarm that rates of liver cancer are rising dramatically among people with HIV, solely as a result of vir...

Simeprevir Is Safe and Effective for Hep C Patients With Advanced Fibrosis

The new therapy simeprevir is generally safe and well-tolerated among hep C patients with advanced liver fibrosis and improves treatment outco...

Daclatasvir, Sofosbuvir Combo Boasts High Hep C Cure Rates Across Genotypes

A combination of daclatasvir and sofosbuvir produced cures in more than 93 percent of hepatitis C patients, with or without the addition of ri...

New Hep C Combo Therapies Safe & Effective for Previous Non-Responders

Danoprevir and mericitabine, two experimental hepatitis C therapies, proved safe and effective among patients with previous treatment experien...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

BMS’s Hep C Therapy Shows 94% Cure Rate in Hard-to-Treat Patients

Bristol-Myers Squibb?s triple combination hepatitis C therapy showed a 94 percent cure rate in hard-to-treat patients.

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

People coinfected with HIV and hepatitis C virus experience high hepatitis cure rates from an Incivek (telaprevir)-based triple combination th...

Gilead’s Hep C Combo Therapy Shows 100% Cure Rate in Small Study

Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.

Abbott’s Interferon-Free Hep C Regimen Boasts Over 90% Cure Rates

Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...
Advertisement
Science News
Newsfeed
Features
Ask Hep